CD8A and neoplasm: One obvious tactic is to block the formation of VM channels directly and thereby reduce the tumour's access to a blood supply, for example using the VM-targeting small-molecule inhibitor CVM-1118, currently under clinical development for several malignancies.94 On the other hand, pre-existing VM vessels may be manipulated to become efficient routes of entry for CD8+ T-cells, such as CAR T-cells or the activated T-cells induced by checkpoint blockade immunotherapy.